Transgene

Transgene Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Transgene (TNG.PA) as of Nov 18, 2026 is 69.32 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 155.28 % — a change of -55.36% (lower).

Cash Conversion

69.32 %

YoY

-55.36%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Transgene is 2024 69.32 % . Cash Conversion Rate (OCF/Net Income) of Transgene was 2023 155.28 % . It decreases by -55.36% lower compared to the previous year.

The Transgene Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2017
109.59 EUR
Jan 1, 2018
-353.61 EUR
Jan 1, 2019
119.19 EUR
Jan 1, 2020
166.80 EUR
Jan 1, 2021
132.62 EUR
Jan 1, 2022
61.89 EUR
Jan 1, 2023
155.28 EUR
Jan 1, 2024
69.32 EUR
The Transgene Cash Conversion history
YEARCash ConversionYoY
69.32 %-55.36%
155.28 %+150.89%
61.89 %-53.33%
132.62 %-20.49%
166.80 %+39.94%
119.19 %-133.71%
-353.61 %-422.66%
109.59 %-17.75%
133.24 %+36.84%
97.36 %-12.83%
111.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Cash Conversion Rate (OCF/Net Income) of Transgene is 69.32 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Transgene changed from 155.28 % to 69.32 %, representing a -55.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Transgene since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene